Compare KraneShares CSI China Internet ETF (KWEB) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Smith & Nephew plc — how do they compare? KraneShares CSI China Internet ETF trades at $27.03, while Smith & Nephew plc trades at $30.16 (market cap $12.64B). The key difference: Smith & Nephew plc pays a 2.57% dividend while KraneShares CSI China Internet ETF pays none. Which is the better fit depends on your goals.
| KWEB | SNN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $42.94 | $38.70 |
52-Week Low | $23.63 | $28.73 |
Market Cap | — | $12.64B |
Enterprise Value | — | $15.41B |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB, the KraneShares CSI China Internet ETF, trades at $27.44, up 2.35% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF offers exposure to leading Chinese internet and AI companies, currently near 52-week lows. Recent news highlights China's AI investment plans and factory rebound driven by AI hardware exports, providing potential growth catalysts amid economic stabilization efforts.
The outlook for KWEB is cautiously optimistic, with attractive valuations relative to Western peers and strong AI-driven growth potential. Key risks include US-China tensions, regulatory changes, and economic volatility. Analyst sentiment is mixed, balancing long-term value against near-term geopolitical and market uncertainties.
Smith & Nephew (SNN) trades at $30.43, down 0.54% on the day, with mixed technical signals showing a neutral overall stance. The company demonstrates improving fundamentals with 2024 revenue of $5.81 billion and net income of $412 million, representing a 7.09% margin. Recent product launches including the LYNX COBLATION Wand and CORI XT robotics platform highlight ongoing innovation. Cash flow trends show strong operational performance with $987 million from operations in 2024.
SNN presents a balanced investment case with improving profitability and product innovation offset by recent earnings misses. The stock trades at reasonable valuations (P/E 21.36, P/S 2.17) with analyst consensus leaning Hold (68%). Key risks include execution challenges and competitive pressures, while catalysts include robotics expansion and wound care leadership. The $500 million buyback program supports shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
